Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses exciting ongoing trials that are assessing whether antibodies can effectively activate amyloid-dissolving macrophages in patients with AL amyloidosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.